Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...
Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
Data from ATH434-201 double-blind Phase 2 trial to be featured in oral session and multiple poster presentations –MELBOURNE, Australia and SAN ...
H. Lundbeck A/S (Lundbeck) today announced that pipeline developments regarding amlenetug, a novel investigational molecule for the potential treatment of Multiple System Atrophy (MSA), will be ...
YOKNEAM, Israel, May 19, 2025 /PRNewswire/ -- Cytora, a clinical stage company developing unique stem cell treatments based on human Oral Mucosa Stem Cells (hOMSC), reported today data of an ongoing ...
The latest announcement is out from Alterity Therapeutics ( (AU:ATH) ).
In this article, we will be taking a look at the 12 Cheap Healthcare Stocks to Buy Now. Teva Pharmaceutical Industries Limited is one of them. Teva Pharmaceutical Industries Limited (NYSE:TEVA), a ...
Research Triangle Park, North Carolina Friday, September 19, 2025, 10:00 Hrs [IST] ...
MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback